共 50 条
- [41] Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial[J]. BLOOD, 2022, 140 : 4834 - 4838Hassoun, HaniJacobus, Susanna J.Richardson, Paul G.Zonder, Jeffrey A.Voorhees, Peter M.Kaufman, Jonathan L.Yee, Andrew J.Scott, Emma C.Torka, PallawiLibby, EdwardReeves, BrandiWang, Michael L.Anderson, Larry D., Jr.Milner, CarterGasparetto, Cristina J.Agha, MounzerKhan, AbdullahHurd, David DuaneAvigan, DavidCostello, CaitlinJakubowiak, AndrzejLonial, SagarRaje, NoopurMedvedova, EvaMcCarthy, Philip L.Orlowski, Robert Z.Nadeem, OmarLaubach, Jacob P.Pasquini, Marcelo C.Giralt, Sergio A.Masone, KellySamur, Mehmet K.Perrot, AuroreMoreau, PhilippeAvet-Loiseau, HerveWeller, Edie A.Munshi, Nikhil C.Anderson, Kenneth C.
- [42] Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E89 - E90Abonour, RafatDurie, BrianJagannath, SundarShah, JatinNarang, MohitTerebelo, HowardGasparetto, CristinaToomey, KathleenHardin, JamesKitali, AmaniGibson, Craig J.Srinivasan, ShankarSwern, ArleneRifkin, Robert
- [43] Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial[J]. BLOOD, 2021, 138Rosinol, LauraOriol, AlbertRios Tamayo, RafaelJesus Blanchard, MaríaJarque, IsidroBargay, JoanHernandez, Miguel-TeodoroMaria Moraleda, JoseCarrillo-Cruz, EstrellaSureda, AnnaMartinez-Lopez, JoaquinKrsnik, IsabelGonzalez Garcia, EstherCasado, FelipeMarti, Josep M.Encinas, CristinaDe Arriba, FelipePalomera, LuisSampol, AntoniaGonzalez-Montes, YolandaCabezudo, ElenaMateos, Maria-VictoriaSan-Miguel, JesusJose Lahuerta, JuanBlade Creixenti, Joan
- [44] FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT).[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Facon, ThierryHulin, CyrilleDimopoulos, Meletios A.Belch, AndrewReece, Donna EllenCatalano, John V.Pinto, AntonioLudwig, HeinzBahlis, Nizar J.Cavo, MicheleMoreau, PhilippeQiu, LuguiLeBlanc, RichardSchots, RikRajkumar, S. VincentMarek, JenniferChen, GuangErvin-Haynes, Annette L.
- [45] Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials[J]. BLOOD, 2015, 126 (23)Lentzsch, SuzanneVillanueva, NicolasNguyen, JamesLandau, HeatherLendvai, NikolettaMiao, SusannaSchecter, Jordan M.Reyna, MariamneMapara, Markus Y.Redner, Robert L.Chung, David J.Lesokhin, Alexander M.Kewalramani, TarunGiralt, SergioComenzo, Raymond L.Landgren, OlaHassoun, Hani
- [46] REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE (VTD) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIES[J]. VALUE IN HEALTH, 2018, 21 : S70 - S70Anjo, J.Rider, A.Bailey, A.Gaudig, M.
- [47] Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study[J]. BLOOD, 2010, 116 (21) : 274 - 275Roussel, MurielleAvet-Loiseau, HerveMoreau, PhilippeHuynh, AnneBenboubker, LotfiHulin, CyrilleMarit, GeraldLeleu, XavierPegourie, BrigitteFruchart, ChristopheCaillot, DenisStoppa, Anne-MarieFacon, ThierryHarousseau, Jean-LucAttal, Michel
- [48] Newly Diagnosed Multiple Myeloma (NDMM): Effect of Age, Renal Insufficiency (RI), & Cardiovascular (CV) Disease (dz) on Overall Survival (OS) & Treatment (tx) Patterns Among Stem Cell Transplant (SCT)-Ineligible Patients (pts) in the United States (US)[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E82 - E82Romanus, DorothyRaju, AdityaSeal, BrianFarrelly, EileenSkacel, TomasBlazer, MarloParameswaran, Hari
- [49] Phase 2 randomized study of daratumumab (dara), lenalidomide (R), bortezomib (V), and dexamethasone (d; Dara-RVd) vs. RVd in patients (pts) with newly diagnosed multiple myeloma (MM) eligible for high-dose therapy (HDT) and autologous stem cell transplantation (ASCT)[J]. ANNALS OF ONCOLOGY, 2017, 28Lin, T.Hydutsky, L.Parros, H.Murphy, S.Pei, H.Londhe, A.Ukropec, J.Qi, M.Lutska, Y.Sharma, M.
- [50] Lenalidomide (LEN) Maintenance Following High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): A Meta-Analysis of Overall Survival (OS)[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E6 - E6McCarthy, PhilipHolstein, SarahPetrucci, Maria TeresaRichardson, PaulHulin, CyrilleTosi, PatriziaBringhen, SaraMusto, PellegrinoAnderson, Kenneth C.Caillot, DenisGay, FrancescaMoreau, PhilippeMarit, GeraldJung, Sin-HoYu, ZhinuanWinograd, BenjaminKnight, Robert